Related references
Note: Only part of the references are listed.Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia
Nobuko Hijiya et al.
CLINICAL CANCER RESEARCH (2020)
Impact of tyrosine kinase inhibitors on the statural growth in children with acute lymphoblastic leukemia
Fang-yuan Zheng et al.
LEUKEMIA RESEARCH (2020)
How I treat chronic myeloid leukemia in children and adolescents
Nobuko Hijiya et al.
BLOOD (2019)
Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group
Uma Athale et al.
PEDIATRIC BLOOD & CANCER (2019)
The small problem when treating childhood chronic myeloid leukemia
Meinolf Suttorp
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2019)
Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia
Nobuko Hijiya et al.
BLOOD (2019)
Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol
Janatani Balakumaran et al.
BMJ OPEN (2019)
Growth disturbances in children and adolescents receiving long-term tyrosine kinase inhibitor therapy for Chronic Myeloid Leukaemia or Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia
Himalee S. Sabnis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial
Lia Gore et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial
Meinolf Suttorp et al.
LEUKEMIA (2018)
Pediatric chronic myeloid leukemia is a unique disease that requires a different approach
Nobuko Hijiya et al.
BLOOD (2016)
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis
Sonali Chaudhury et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A. Hochhaus et al.
LEUKEMIA (2016)
Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia
Jill Samis et al.
PEDIATRIC BLOOD & CANCER (2016)
Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience
Fiorina Giona et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
Javid J. Moslehi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Growth deceleration in children treated with imatinib for chronic myeloid leukaemia
Frederic Millot et al.
EUROPEAN JOURNAL OF CANCER (2014)
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
Hagop M. Kantarjian et al.
BLOOD (2011)
Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial
Frederic Millot et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Distinct Impact of Imatinib on Growth at Prepubertal and Pubertal Ages of Children with Chronic Myeloid Leukemia
Haruko Shima et al.
JOURNAL OF PEDIATRICS (2011)
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
Hagop M. Kantarjian et al.
LANCET ONCOLOGY (2011)
Share Paper
